Ero Copper (ERO) +17%

Ero Copper Corp. engages in the exploration, development, and production of mining projects in Brazil. 

Its flagship asset includes Caraíba operations that comprise the production and sale of copper concentrates located in northeastern Bahia State, Brazil, as well as gold and silver produced and sold as by-products. 

• Sector: Basic Materials
• Industry: Copper
• Full Time Employees: 3,690
• Incorporated in 2016 
• Headquartered in Vancouver, Canada
• https://erocopper.com

==Alarum Technologies Ltd. (ALAR) reported earnings on Wed 26 Nov 25 (b/o)

 

Alarum Technologies Ltd. (NASDAQ: ALAR) was formerly known as Safe-T Group Ltd. and rebranded to Alarum (ALAR) in Jan 2023

Sector: Technology

Industry: Software - Infrastructure

Full Time Employees: 68

Founded in 2013 

Headquartered in Tel Aviv, Israel

https://www.alarum.io

Alarum Technologies today reported record Q3 2025 results—revenue $13.0M (+81% y/y), net profit $0.1M and $1.2M adjusted EBITDA—and guided Q4 to about $12M revenue and ~$1M adjusted EBITDA, citing strong AI training-data demand.

===Novo Nordisk (NVO) : Ozempic pill failed to slow Alzheimer’s progression in two large studies.

 

Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression

• Co announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease. The two trials were randomised, double-blinded, enrolled a total of 3808 adults and evaluated the efficacy and safety of oral semaglutide compared to placebo on top of standard of care. The decision to pursue an Alzheimer's disease indication with semaglutide was based on real-world evidence studies, pre-clinical models as well as post-hoc analyses from diabetes and obesity tria
• The evoke and evoke+ trials did not confirm superiority of semaglutide versus placebo in the reduction of progression of Alzheimer's disease, as measured by the change in Clinical Dementia Rating -- Sum of Boxes score compared to baseline. While treatment with semaglutide resulted in improvement of Alzheimer's disease-related biomarkers in both trials, this did not translate into a delay of disease progression.
• In the evoke trials with patients aged 55-85, suffering from mild cognitive impairment or mild dementia due to Alzheimer's disease, semaglutide appeared to have a safe and well-tolerated profile consistent with previous semaglutide trials. To date, more than 37 million patient-years of semaglutide exposure have occurred across

==Walmart (WMT) moving its listing to the Nasdaq from the NYSE

• The biggest U.S. retailer and private-sector employer posts Q3 earnings and revenue above estimates, raises full-year guidance, and announces transfer of stock listing to Nasdaq. 

Walmart is moving its stock listing to the Nasdaq Stock Market from the New York Stock Exchange.

The world's largest retailer on Thursday said its shares will begin trading on Nasdaq on Dec. 9 under its current WMT symbol. Walmart said the move "aligns with the people-led, tech-powered approach to our long-term strategy."

The NYSE has been the Bentonville, Ark., company's home since 1972.

Walmart's move would position the retailer to join the Nasdaq-100, an index of the 100 largest nonfinancial companies listed on the exchange. Walmart sports a market capitalization topping $808 billion, which would put it 10th on the current roster.

Joining the Nasdaq-100 could drive the buying of Walmart shares by funds that track the index. Walmart has been part of the Dow Jones Industrial Average since 1997.